DiogenX

General Information

Company Name

DiogenX

Founded Year

2020

Location (Offices)

France +1

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Life Sciences

Funding Stage

Series A

Social Media

DiogenX - Company Profile

DiogenX is a preclinical stage biotech company headquartered in France, founded in 2019. The company focuses on developing pancreatic beta-cell modulators for treating Type 1 and Type 2 Diabetes. Dr. Patrick Collombat's laboratory (Inserm, CNRS, Nice University) in France serves as the company's foundation. DiogenX's pioneering therapy aims to be the foremost beta-cell regeneration medication for tackling diabetes. The company received a significant boost with a €33.50M Series A investment on 10 May 2023, led by Omnes Capital, Sunstone Capital, T1D Fund, BIVF, Eli Lilly, Roche Venture Fund, and AdBio partners. With its innovative approach and strong financial backing, DiogenX is poised to make a significant impact on diabetes treatment.

Taxonomy: Biotech, Diabetes, Pancreatic beta-cell modulators, Therapeutic options, Preclinical stage, Innovative therapy, Biologics, Type 1 Diabetes, Type 2 Diabetes, Regeneration medication, Dr. Patrick Collombat, Inserm, CNRS, Nice University, France

Funding Rounds & Investors of DiogenX (2)

View All

Funding Stage	Amount	No. Investors	Investors	Date
Series A	€33.50M	7	AdBio partners, Boehringer Ingelheim Venture Fund	10 May 2023
Seed Round	€4.50M	3	AdBio partners, Boehringer Ingelheim Venture Fund	16 Jun 2020